Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: Cancer Research (bridge funding)

McMaster University

$100,000.00

Adiponectin Signaling in Cancer

EF 2008-09

Résumé
Obesity is emerging as an established risk factor for cancer. In several cancers such as prostate and breast cancer, obese patients tend to have worse prognosis than normal weight patients. The link between obesity and cancer is not well understood. One possible explanation is the effects of hormones that are exclusively secreted from the fat tissue. The blood levels of one of these hormones, adiponectin, are inversely related to body weight, and therefore are reduced in obese patients. Previous work from our laboratory and others demonstrate that adiponectin acts as a tumour suppressor. We will study the molecular response of prostate and kidney cancer cells, all of which are associated with obesity, to adiponectin in order to elucidate the mechanism for its tumour suppressive effect. This research is expected to provide understanding for the influence of obesity on cancer risk and basis for the development novel drug therapy for cancer.
Programme
Operating Grant - PA: Cancer Research (bridge funding)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
177837
Name
Pinthus Jehonathan H
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Adiponectin Signaling in Cancer
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Cancer Research (bridge funding)
Keyworddelim
Adiponectin; Cancer; Kidney (Renal) Cancer; Obesity; Prostate Cancer; Protein Interaction
Abstract
Obesity is emerging as an established risk factor for cancer. In several cancers such as prostate and breast cancer, obese patients tend to have worse prognosis than normal weight patients. The link between obesity and cancer is not well understood. One possible explanation is the effects of hormones that are exclusively secreted from the fat tissue. The blood levels of one of these hormones, adiponectin, are inversely related to body weight, and therefore are reduced in obese patients. Previous work from our laboratory and others demonstrate that adiponectin acts as a tumour suppressor. We will study the molecular response of prostate and kidney cancer cells, all of which are associated with obesity, to adiponectin in order to elucidate the mechanism for its tumour suppressive effect. This research is expected to provide understanding for the influence of obesity on cancer risk and basis for the development novel drug therapy for cancer.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pinthus, Jehonathan H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~